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Incorporating liquid biopsies into
treatment decision-making: obstacles
and possibilities
Nick Beijez, n.beije@erasmusmc.nl, John W.M. Martensz and Stefan Sleijferz
Circulating tumor cells (CTCs) and cell-free DNA (cfDNA) together with newer emerging liquid biopsies
have a unique potential to deal with key issues in oncology. For example, they can be used to assess
prognosis, direct treatment with certain kinds of drug, or provide information about response to
treatment. However, despite an overflow of literature on the subject, clinical implementation of these
liquid biopsies has been scarce. This is mainly because there is a lack of preanalytical standardization,
multiple different techniques or platforms are being used, and a lack of prospective studies investigating
a meaningful clinical question are performed. Here, we provide an overview of the current state of liquid
biopsies and make suggestions for how liquid biopsies can reach the tipping point.
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In the era of precision medicine, liquid biopsies
have attracted significant interest for personalizing
the treatment of patients with cancer. The premise
of liquid biopsies is that, by obtaining a simple
blood sample, all sorts of cancer-related charac-
teristics can be determined in real time, and can be
used to personalize cancer treatment. However,
the clinical utility of liquid biopsies is yet to be
confirmed. Here, we discuss the current standing of
liquid biopsies in oncology, their highlights until
now, as well as their pitfalls and caveats.
Liquid biopsies: lots to choose from
The current landscape involves multiple types of
liquid biopsy. Most of the research has been
done on CTCs and cfDNA. CTCs are intact tumor
cells that have detached from a solid tumor,
whereas cfDNA is fragmented DNA comprising1359-6446/ã 2019 Elsevier Ltd. All rights reserved.
https://doi.org/10.1016/j.drudis.2019.05.028 germline DNA and potentially circulating tumor
DNA (ctDNA) that originates mainly from apo-
ptotic tumor cells (Fig. 1). Given that cfDNA only
offers the possibility to analyze DNA, CTCs
theoretically offer the analysis of all molecular
materials, including RNA and proteins in the
same cell. There are also emerging liquid bi-
opsies, such as cell-free RNA, extracellular vesi-
cles, such as exosomes and microvesicles,
circulating proteins, and platelets exhibiting
tumor-specific RNA profiles. Promising data on
the use of these emerging liquid biopsies in
cancer screening have been presented [1–4],
but, given the relative scarcity of data on these
newer liquid biopsies, we focus here on CTCs
and cfDNA. For both, there are some clinical data
underlining their potential relevance for per-
sonalizing cancer treatments, but robust evi-
dence showing their clinical utility is warranted.Circulating tumor cells
The CellSearch system is currently the only
system approved by the US Food and Drug
Administration (FDA) for enumerating CTCs in
patients with metastatic breast, colorectal, or
prostate cancer. The system enriches for all cells
expressing EpCAM by using anti-EpCAM mag-
netic beads. Subsequently, cells are stained for
anti-cytokeratin (CK) 8/18/19 (positive on CTCs),
DAPI (a nucleus marker), and anti-CD45 (to
exclude contaminating leukocytes) to identify
CTCs. The method has shown to be highly
specific, given that CTCs are rare in healthy
donors [5]. The prognostic value of CTCs
counted with CellSearch has been shown not
only for many different metastatic epithelial
malignancies, but also in patients with non-
metastatic cancer. For example, in metastatic
breast cancer (MBC), a CTC count of five or morewww.drugdiscoverytoday.com 1715
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FIGURE 1
Current leading liquid biopsies: circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). From the solid tumor, which can either be the primary tumor or
a metastatic site, tumor cells can extravasate and appear in the blood as CTCs or go into apoptosis and shed their DNA. CTCs are intact cells and can form distant
metastases or go into apoptosis. CtDNA is cell-free DNA (cfDNA) that is mainly from apoptotic or necrotic tumor cells and has unknown biological relevance.
Both CTCs and cfDNA can be isolated from whole blood using sophisticated techniques and then be quantified or subjected to multiple molecular analyses.
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similarly, patients with primary breast cancer
with one or more CTCs have decreased overall
survival [6,7]. In addition, changes in CTCs have
been associated with response. However, al-
though enumerating CTC undoubtedly has
clinical validity, studies investigating clinical
utility have been rare and, thus, the test is
seldom used by clinicians.
One study randomizing patients based on
CTC changes during treatment for MBC dem-
onstrated no survival benefit for switching to
another line of systemic treatment based on CTC
counts rather than on traditional means [8].
Similarly, a study in which patients with HER2-
negative primary breast cancer with detectable
CTCs after surgery and standard (neo)adjuvant
therapy received additional trastuzumab
showed no additional benefit [9]. The only study
demonstrating a possible benefit of counting
CTCs for treatment decision-making was re-
cently presented and demonstrated that a
baseline CTC count can be used safely to direct
patients with MBC to receive either first-line
chemotherapy (if five or more CTCs) or endo-
crine treatment (if less than five CTCs) [10].
Interestingly, approximately half of the patients
who the treating physician intended to give
chemotherapy based on clinical grounds could
be safely de-escalated to receive endocrine
therapy. However, given that patients with MBC
now increasingly receive combined treatment
with CDK4/6 inhibitors and endocrine therapy, it
is unlikely that these findings will result in1716 www.drugdiscoverytoday.comwidespread changes in the treatment of such
patients. The lack of true clinical utility of
counting CTCs means that baseline CTC counts
and changes in CTC counts are now mainly used
in clinical trials only as a prognostic marker or as
early response marker.
One of the main concerns with CellSearch is
its dependency on EpCAM, with the potential of
missing out on EpCAM-negative CTCs [11].
Therefore, a plethora of alternative assays have
become available that have tried to address this
issue: for example, by using alternative markers
to detect CTCs or using size-based properties of
CTCs to enrich for them. However, head-to-head
comparisons of the several available assays for
CTC detection have been anecdotal. One of the
main problems in comparing assays is the ab-
sence of a ground truth, meaning that, for some
CTC detection assays, increased sensitivity
compared with CellSearch has been described,
although it is unclear whether this was at the
expense of specificity. It is unlikely that, for
counting CTCs, any other assay than CellSearch
will undergo such vigorous validation of its
prognostic value in so many tumor types and
settings.
Beyond counting CTCs
Counting CTCs is a rather 1D use of CTCs. Most
CTC detection assays have described methods
to characterize CTCs at the RNA, DNA, and
protein level. Initially, these types of analysis
were limited to the detection of genes or
mutations on a mixed pool of CTC-enrichedmaterial and leukocytes. Although it is possible
to identify somatic mutations and RNA profiles
on these materials, it is labor intensive and,
moreover, specificity issues arise when
attempting to measure any tumor-specific sig-
nal in a background of leukocyte-derived ma-
terial. One of the most clinically relevant markers
that have come from CTCs is the androgen
receptor splice variant V7 (AR-V7) in metastatic
prostate cancer (mPC), which is a RNA variant
that predicts for resistance to antiandrogen
therapies in mPC [12,13]. Prospective clinical
studies investigating whether the CTC AR-V7
status is useful to guide treatment decision-
making in mPC are ongoing.
Given its great promise, many efforts are
underway to further improve methods to mo-
lecularly characterize CTCs. For example, efforts
to characterize CTCs at the single cell level by
DNA or RNA sequencing have taken off with the
availability of several methods to isolate single
cells [14], but have so far been limited to proof-
of-concept studies. Although single CTC char-
acterization will probably offer more informa-
tion on heterogeneity, it is unclear to what
extent this will reflect the entire landscape of
tumor heterogeneity, especially if performed in
limited numbers of CTCs.
Another method to improve CTC characteri-
zation is by increasing the blood volume that is
analyzed, sometimes even by using leukapher-
esis [15]. Although using leukapheresis does
yield more CTCs to analyze [16], it somewhat
compromises the minimally invasive and easy-
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requiring purification of CTCs among contami-
nating blood leukocytes.
Another strategy for obtaining higher num-
bers of CTCs for downstream analysis is culturing
of CTCs, for example with the intent to subse-
quently run drug-sensitivity analyses on them
[17]. Although multiple groups have described
successful long-term cultures of CTCs, the
chance of success is low and seemingly limited
to patients with very high CTC counts of >300
CTCs/7.5 ml [18]. Given this low success rate and
because it takes several weeks to months to
culture these CTCs, broad implementation
appears unlikely, other than perhaps for groups
of patients with higher levels of CTCs, such as
most patients with small-cell lung cancer [19].
Cell-free DNA
Even more as is the case for CTCs, many different
assays to detect aberrations in cfDNA are now
commercially available. Compared with CTC de-
tection, cfDNA is more easily analyzed with tools
such as next-generation sequencing (NGS)
machines and PCR machines already available in
most research laboratories. ctDNA is the fraction
of cfDNA that is tumor derived. The percentage of
ctDNA is often <1%, meaning that classical
techniques, such as Sanger sequencing and
quantitative PCR, often lack the sensitivity to
detect tumor-specific mutations. Initially, mostly
digital PCR (dPCR)-based approaches were used.
However, using dPCR, only a limited amount of
mutations can be detected in one run. Therefore,
NGS protocols using unique molecular identifiers
are now more often used, increasing sensitivity
and allowing the detection of ctDNA mutations in
multiple genes of interest. Newer methods even
allow for the detection of copy number variations
using low-coverage whole-genome sequencing
[20] or methylome profiles [21].
Preanalytical and postanalytical
processing
Regardless of the technique, preanalytical steps,
such as sample collection and processing, have
to occur and can greatly affect the final results.
There are significant differences between the
various protocols, as described in the literature.
It is known that blood samples have to be
processed within 24 h or in special tubes with a
stabilizing agent (e.g., CellSearch tubes or BCT
tubes) to prevent lysis of leukocytes increasing
the amount of nontumor-derived cfDNA,
thereby lowering the sensitivity [22]. Addition-
ally, some cfDNA isolation kits select for smaller
or longer cfDNA fragments than other kits [23],
of which the significance is unknown. Besidesthese factors, there is also limited insight into
the effect of freezing and thawing of samples
and to what extent various comedications, un-
derlying comorbidities, or, for example, circadian
rhythms influence cfDNA concentrations [24].
After sample processing, the postanalytical
phase in which the cfDNA somatic mutations
have to be identified is also crucial. Although
commercially available cfDNA assays usually
come with associated software, the subsequent
analysis and calling of somatic mutations is
often left to the users.
An issue related to these downstream anal-
yses is how somatic variants should be reported.
Somatic variants are most commonly expressed
as variant allele frequency (VAF) or the number
of mutant copies/ml. With the availability of
highly sensitivity assays, we do not know
whether detection of a variant is clinically rele-
vant at a low VAF or low mutant copy number. A
complicating factor is also that the VAF in par-
ticular is influenced by the background. Hence,
an increase or decrease in background (e.g.,
increased apoptosis of leukocytes) can change
the VAF, which might especially be important in
monitoring of VAF during treatment. The num-
ber of mutant copy numbers appears to be more
constant [22]; however, it is unclear what change
in VAF or copy number is both biologically and
clinically relevant.
Given all the steps that might influence cfDNA
analysis, Torga and Pienta [25] recently sent
blood samples from patients taken at the same
moment to two CLIA-licensed commercial lab-
oratories for cfDNA NGS sequencing for head-to-
head comparison. The results were worrisome,
because results from 64% of the tested samples
were incongruent between the two laboratories.
At this point, it is unclear how the differences
between both assays can be explained.
Potential clinical use of ctDNA
Although it is clear that there is still some way to
go before optimal analytical validity is reached,
there are also exiting data published that open
doors to all kinds of key clinical problems in
oncology. This includes the use of ctDNA as a
predictive marker for certain treatments, as a
marker to detect disease relapse, as a marker to
detect emerging resistance to a (targeted)
treatment, or as a means to screen people for
the presence of cancer.
Nowadays, cfDNA assays are most commonly
used as predictive markers in the setting of
EGFR-mutated metastatic non-small cell lung
cancer (mNSCLC), because the presence of ac-
tivating EGFR mutations in treatment-naive
mNSCLC is a prerequisite for treatment withEGFR tyrosine-kinase inhibitors (TKIs). The only
cfDNA test that is currently approved by the FDA
is the cobas test, which is approved to identify
EGFR exon 19 deletions, L858R, and T790 M
mutations. Overall concordance between tissue
and cfDNA using this test has been high at 89–
91% [26,27] and patients with mNSCLC har-
boring EGFR mutations in cfDNA identified using
this test benefitted from treatment with EGFR
TKIs compared with placebo [26]. Therefore,
cfDNA is increasingly used to screen patients for
first-line EGFR TKI treatment and most clinicians
use it if tissue specimens are unavailable [27].
For the T790 M mutation in the EGFR, conferring
resistance to TKIs in patients with mNSCLC and
rendering these patients suitable for treatment
with osimertinib, some groups even advocate
using cfDNA initially to detect EGFR T790M
followed by a tumor biopsy in case of negative
results [27]. However, the FDA approved the
T790M EGFR cfDNA test only when it is not
possible to obtain a tissue biopsy at the time of
progression on a TKI. Their cautiousness is
probably because of poorer concordance rates
between tissue and cfDNA for EGFR T790M
mutations at 70% [28]. However, concordance
studies between tissue and cfDNA will never
show perfect similarity. For driver mutations,
such as EGFR exon 19 deletions and L858R
mutations, which are present in most tumor
cells, concordance will probably be good. By
contrast, for subclonal or resistance mutations,
such as EGFR T790M, concordance rates will
likely be lower. These discrepancies between
tissue and cfDNA might occur because of ana-
lytical issues, low numbers of ctDNA, or bio-
logical factors, such as heterogeneity.
Another important factor for cautiousness
with using cfDNA without tissue-based confir-
mation is that there is no formal proof that
cfDNA-mutant-positive, tissue-mutant-negative
patients have similar responses to therapy as
cfDNA-mutant-positive, tissue-mutant-positive
patients. For example, patients with EGFR
T790M-positive cfDNA had poorer progression-
free survival (PFS) on osimertinib if they had a
T790M-negative tumor than if they had a
T790M-positive tumor (PFS 4.2 versus 9.3
months, respectively; P = 0.0002) [28].
Besides the use of cfDNA in EGFR-mutated
mNSCLC, cfDNA is not yet routinely used as a
predictive marker to select patients with cancer
for certain targeted therapies. Although a recent
report underlined its potential use to direct
patients with an actionable mutation to ap-
propriate Phase I trials within a timeframe ac-
ceptable for clinical decision-making [29],
further trials are eagerly awaited.www.drugdiscoverytoday.com 1717
PERSPECTIVE Drug Discovery Today Volume 24, Number 9  September 2019
Featu
res
P
ER
SP
EC
TIV
EWith respect to the use of ctDNA to detect
early relapse, there have been examples in
multiple non-metastasized tumors in which
somatic cfDNA mutations were detected after
curative operative treatments and were associ-
ated with decreased relapse-free survival
[30,31]. This might mean that patients at risk for
relapse can be identified early and treated ac-
cordingly, although the extent to which there
might be some type of lead-time bias remains to
be seen.
Mutations in cfDNA can also be used as a
surrogate of drug response in longitudinal
monitoring. For example, interesting data were
described for KRAS mutations that cause resis-
tance to monoclonal antibodies targeting the
EGFR (EGFR-MoAbs). There is some evidence
that, upon discontinuation of EGFR-MoAbs,
KRAS mutations decay and drug sensitivity is
regained, which might mean that these patients
can be rechallenged with EGFR-MoAbs [32],
which is now being tested in a proof-of-concept
study (CHRONOS trial, NCT03227926).
Lastly, it has been suggested that cfDNA
could be used as a cancer-screening tool. In an
analysis of 1005 patients with non-metastatic
cancers, a test for detecting cancer based on
ctDNA mutations and protein tumor markers
had a median sensitivity of 70% and specificity
of >99% [33]. Although this highlighted the
potential of cfDNA analyses to detect cancer at
an early stage, its application as a screening
tool in a healthy population still has a long
way to go, especially because the positive
predictive value of the test declined signifi-
cantly when tested in a population in which
the prevalence of cancer was low, which isTABLE 1
Factors influencing the clinical validity and 
Problem So
Preanalytical
Large variety in use of blood tubes and cfDNA
isolation assays
Es
fo
Unknown influence of circumstantial biological
factors (e.g., comedications, comorbidity)
Re
co
Analytical
Multitude of assays used to detect and
characterize ctDNA
Vi
pe
Postanalytical
Somatic variants reported in different variables Us
Clinical utility
Unknown relevance of finding a somatic
mutation at (extremely) low frequency
Pe
a s
tre
Unknown what change in somatic mutation
over time is clinically relevant
Es
so
tri
1718 www.drugdiscoverytoday.comtypically the case when screening the general
population [34].
Reaching the tipping point
Research on liquid biopsies has skyrocketed
over the past decade and has led to novel
insights into cancer biology. However, incor-
poration of liquid biopsies into clinical work-
flows remains a major challenge. Given the
plethora of articles on liquid biopsies that have
been published to date, it is disappointing that
approval only exists for the CellSearch CTC
assay and certain cfDNA assays able to detect
mutations in the EGFR receptor. With respect to
cfDNA, a recent ASCO and College of American
Pathologist joint review even concluded that
there is ‘little evidence of clinical validity and
clinical utility to support widespread use of
ctDNA assays in most patients with advanced
cancer’ [35].
One of the factors contributing to the lack of
clinical applicability is the current overabun-
dance of liquid biopsy assays. This is especially
the case in the cfDNA field, in which dozens of
assays are now commercially available and also
an important subset of assays developed in-
house by academia. All of these assays have their
own limit of detection, sensitivity, and specific-
ity, meaning that findings on one particular
liquid biopsy platform are not necessarily ap-
plicable to all other platforms, hampering clin-
ical applicability and underlining the need for
external quality assessment studies before im-
plementation in routine diagnostics (general
issues in cfDNA research are listed in Table 1).
Another key issue is that trials that examine a
true change in clinical decision-making basedutility of cfDNA
lution
tablishing evidence-based standardized protocol
r blood collection and processing
searching influence of these circumstances in large
hort studies
gorous analytical validation of each assay and
rform cross-assay comparisons
e of mutant copy number/ml instead of VAF
rforming clinical trials investigating at which cut-off
omatic mutation is related to response to a targeted
atment or clinical residual disease
tablish biological and analytical variation for a given
matic mutation and subsequently perform clinical
als that take this variation into accounton liquid biopsies are rare. From 642 trials
registered at clinicaltrials.gov that are evaluating
liquid biopsies in some way, only 21 trials (3.3%)
are investigating a particular intervention based
on liquid biopsies (supplemental information
online). In almost half of these interventional
studies, patients received a particular interven-
tion (such as a targeted treatment) based on
baseline CTC or cfDNA status without the in-
clusion of a control group that does not receive
that particular intervention, meaning that, in the
case of a positive study result, these studies are
unlikely to result in immediate changes in
clinical practice. Although observational studies
are also of key importance in increasing our
understanding of cancer and might be hy-
pothesis generating, our current understanding
of liquid biopsies does allow for more direct
interventional research, but at this point that
seems to be rare.
Concluding remarks
In conclusion, for liquid biopsies to eventually
reach the tipping point, in addition to as much
harmonization of preanalytical and analytical
conditions as possible, the need for more clinical
trials that investigate a meaningful clinical
question is especially high. Whether this re-
search is done with CTCs, cfDNA, or one of the
emerging liquid biopsies is not that important:
the one that proves to be of clinical utility, in
combination with analytical validity, will even-
tually be adapted by the community.
Appendix A. Supplementary data
Supplementary material related to this article
can be found, in the online version, at doi:
https://doi.org/10.1016/j.drudis.2019.05.028.
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